<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230810059110N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-11-01</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Investigating  the effect of Syrup based on Naqu Fawakeh on liver enzymes in children with ALL undergoing chemotherapy ,a double blind randomized controlled trial.</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of Syrup based on Naqu Fawakeh on liver enzymes in children with ALL undergoing chemotherapy ,a double blind randomized controlled trial.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>106</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72003</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The permutation block randomization method with blocks of four will be used (using random allocation software). This method is one of the most widely used random methods that guarantees equality of groups to a large extent. For this purpose, first we name the groups A or B. then we consider the different permutations of 4 letters of these two letters, of course, you can also consider the blocks with the size of 2 and 6, etc. But blocks with size 4 have been used more. Four  permutations of two letters A and B are AABB, ABAB, ABBA, BBAA, BABA, BAAB. Each of these is a block of size 4, which includes two Patients from the experimental group and two from control Patients , for example, AABB permutation means that the first and second Patients are selected from  group A (group A can be the test or the control group) and The second two Patients are assigned to group B (group B can be the experiment or the control group), then randomly by throwing a coin, we determine which A or B are the experiment group and which  one is control group, for example, suppose A is the experimental group and B is the control group. Then we assign each of these 6 permutations to the numbers from 1 to 6 in the following order.
1. AABB
2. ABAB
3. ABBA
4. BBAA
5. BABA
6. BAAB
Now, using the table of random numbers, we extract numbers from the table sequentially, and we consider the digit of the extracted random numbers, which are one of the numbers 0 to 9, and depending on whether one of the numbers 1 to 6 comes, each of the blocks We select the numbers assigned to these numbers. With this calculation, we need 27 random numbers, which we use the rule of using the table of random numbers to extract these 27 numbers until 27 blocks of 4 are selected. If the numbers 0, 7, 8, and 9 come, we ignore them and continue this order to provide a complete list for the entire sample volume.

Randomization using a computer can also be used for implementation in this regard.
The randomization sequence is determined by the statistician in coordination with the pharmacist.
The questioner enters the participants into the plan and determines the block of each patient according to the variables, then each patient is given a code, and according to that, the bottle with the corresponding code label is delivered to the patient by the trained personnel in the pharmacy of Imam Reza Hospital.  The questioner does not know the contents of the bottles.

 Hide the random allocation, ten-digit codes will be printed on the bottles in coordination with the statistician and the pharmacist. The codes related to each block are randomized, identified and provided to the patient by the interviewer before the initial evaluation, and Naqu Fawakeh (Fitobile) and Silymarin (Livertrap) syrup are in bottles that are completely similar in color and shape. and similar labels are attached to the company's bottle, Blinding description: Participants and service providers are blinded to the intervention until the end of the design and presentation of statistical results. Naqoo Fawake Syrup (Fitobile) and Silymarin (Livertrap) are in completely similar bottles in terms of color and shape, and similar labels are attached to the company's bottles.

To hide the random allocation, ten-digit codes will be printed on the bottles in coordination with the statistician and the pharmacist. The codes related to each randomized block are specified and provided to the patient by the interviewer before the initial evaluation.
The pharmacist is aware of the contents of the bottles (Effervescence and Silymarin).
The statistician who prepares the blocks and tables of random numbers is aware of the content of the codes.
  In order to blind the researcher, after the visit and receiving the relevant code, the patient goes to Imam Reza Pharmacy to receive the medicine, and the medicine is delivered to the patient based on the code by the trained staff of the pharmacy, and the way to take the medicine is given to the patient and his companion based on age and weight. They explain.</study_design>
      <phase>3</phase>
      <hc_freetext>Elevation of liver enzymes caused by chemotherapy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: Naqu Fawake syrup containing Bukhara plums, black plums, mangosteens, jujubes, jaggery, tamarinds, apricots, and red sugar, which is currently manufactured under the brand name of Fitobile Syrup by Faratab Company, in the amount of 5 cc 3 times a day, 3 hours later Each meal at the age of 5 to 12 years and 1 tablespoon a day 3 hours after each meal at the age of 12 to 17 years is given for 8 weeks. Intervention 2: Control group: Control group: The control group is given silymarin syrup from Hakim Momin Tabrizi company and according to the amount of 120 mg of silymarin per 5 cc, in children under 30 kg 2 cc 3 times a day after each meal and for children over 30 Kilo 4 cc is given 3 times a day after each meal.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Confidentiality</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Yasman Vazani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zand St., Medical School, 7th floor, Department of Iranian Medicine</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134845794</zip>
        <telephone>+98 71 3234 5145</telephone>
        <email>Yasaman.vazani@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Yasman Vazani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zand St., Medical School, 7th floor, Department of Iranian Medicine</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134845794</zip>
        <telephone>+98 71 3234 5145</telephone>
        <email>Yasaman.vazani@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with ALL based on bone marrow aspiration and immunophenotype, aged 5 to 17 years, in the maintenance phase of treatment  by methotrexate and 6-mercaptopuril, with liver enzymes level 2 times or more  higher than the maximum normal level
Willingness to participate in the study
.</inclusion_criteria>
      <agemin>5 years</agemin>
      <agemax>17 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The occurrence of any allergy and intolerance to the drug.
Diagnosis of liver disease during planning.
The patient's unwillingness to continue treatment.
Taking drugs that interfere with the herbs in the composition.
history of drug sensitivity to the plants in the syrup:Prunus cerasus,Prunus domestica,Alhagi pseudalhagi ,Zizyphus jujube,Cordia myxa ,Tamarindus indica,Prunus armeniaca,Saccharum officinarum
The patient has diarrhea. (CTCAE questionnaire)[39]
history of liver disease, viral hepatitis, HIV, diabetes, other malignancies, and chronic intestinal disease.
Taking drugs with the risk of cholestatic liver damage or damaging liver cells: drugs causing liver cholestasis: amoxicilline and clavulanic acid with consumption of more than 90 mg per kilogram per day, anabolic steroids, chlorpromazin, clopidogrel, erythromycin, irbesartan, mirtazapine, estrogen , terbinafine, drugs that damage liver cells and cause liver cholestasis, amitriptyline, azathioprine: captopril, carbamazepine, clindamycin, co-trimoxazole, cyproheptadine, enalapril, flutamide, nitrofurantoin, phenobarbital, phenytoin, sulphonamide, trazodone, verapamil</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K71.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Toxic liver disease with hepatitis, not elsewhere classified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: Naqu Fawake syrup containing Bukhara plums, black plums, mangosteens, jujubes, jaggery, tamarinds, apricots, and red sugar, which is currently manufactured under the brand name of Fitobile Syrup by Faratab Company, in the amount of 5 cc 3 times a day, 3 hours later Each meal at the age of 5 to 12 years and 1 tablespoon a day 3 hours after each meal at the age of 12 to 17 years is given for 8 weeks.</i_keyword>
      <i_keyword>Control group: Control group: The control group is given silymarin syrup from Hakim Momin Tabrizi company and according to the amount of 120 mg of silymarin per 5 cc, in children under 30 kg 2 cc 3 times a day after each meal and for children over 30 Kilo 4 cc is given 3 times a day after each meal</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Alanine transaminase (ALT). Timepoint: before the start of the intervention and 28, 84, 56 days after the start of the drug. Method of measurement: Blood test.</prim_outcome>
      <prim_outcome>Aspartate transaminase(ASP). Timepoint: before the start of the intervention and 28, 84, 56 days after the start of the drug. Method of measurement: Blood test.</prim_outcome>
      <prim_outcome>Alkaline Phosphatase( ALP ). Timepoint: before the start of the intervention and 28, 84, 56 days after the start of the drug. Method of measurement: Blood test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Constipation. Timepoint: At the beginning of the study (before the start of the intervention) and 28, 56, 84 days after the start of the drug. Method of measurement: Criteria Terminology Common For Adverse Events (CTCAE) version4 ,questionnaire.</sec_outcome>
      <sec_outcome>Nausea and Vomiting. Timepoint: At the beginning of the study (before the start of the intervention) and 28, 56, 84 days after the start of the drug. Method of measurement: MAT questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-26</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Zand St.,   Shiraz University of Medical Sciences Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
